Skip to main content

Volume 3 Supplement 2

30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope

Although promising, the combination of long synthetic peptides and CpG-B oligodeoxynucleotides has not yet been tested as cancer vaccine. In this Phase I trial, 19 patients received a mean of 8 (range 1-12) monthly vaccines s.c. composed of the long synthetic NY-ESO79-108 peptide and CpG-B (PF-3512676), emulsified in Montanide ISA-51. In 18/18 evaluable patients, vaccination induced responses of both CD8 and CD4 T cells, starting early after initiation of immunotherapy and lasting for many months. The T cells responded antigen-specifically, with strong secretion of IFNγ and TNFα, irrespective of patient's HLAs. The most immunogenic region of the vaccine peptide was the NY-ESO-183-97 sequence, inducing HLA-DR or -DP restricted CD4 T cell responses in all patients tested. We discovered a novel and highly immunogenic epitope (HLA-DR7/NY-ESO-187-99); 5/5 HLA-DR7+ patients generated strong CD4 T cell responses, as detected directly ex-vivo with fluorescent multimers. Thus, vaccination with the long synthetic NY-ESO-179-108 peptide combined with the strong immune adjuvant CpG-B, a TLR-9 agonist, induced integrated, robust and functional CD8 and CD4 T cell responses in melanoma patients, supporting the further development of this immunotherapeutic approach.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Camilla Jandus.

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baumgartner, P., Nunes, C.C., Cachot, A. et al. Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope. j. immunotherapy cancer 3, P437 (2015). https://doi.org/10.1186/2051-1426-3-S2-P437

Download citation

Keywords

  • Peptide
  • Melanoma
  • Cell Response
  • Synthetic Peptide
  • Melanoma Patient